NCT02851693

Brief Summary

The diagnosis of cutaneous lesions often involves the use of surgical and invasive procedures such as biopsy or excision in order to analyze the structure and appearance of the fabric pathologists. With recent advances in optical and electronic fields, considerable efforts were produced to build high-performance optical instruments, able to transcribe the internal structure of the skin with varying degrees of depth and variable resolution. The imagery is now an area of great interest for medical diagnosis: non-invasive, quick, and in real time. This area is booming and new optical instruments are created to eventually be able to offer a reliable alternative to invasive techniques. The optical properties of different tissues have been studied for several years by different research groups: the coefficient of light absorption by the tissue both in vivo and in vitro, the coefficient of light scattering or the index refractive were characterized in various tissues that make up the skin. Other studies have focused on melanoma detection by multispectral optical techniques, or via the technique of optical coherence tomography (OCT) performed on lesions suspicious for cancer, but without linking criteria between these two techniques. However, no study to date and to our knowledge has been able to demonstrate the different optical parameters obtained with OCT and can be directly connected to known and histopathological parameters commonly used in the diagnosis of lesions skin. This study aims to verify if it is possible to determine the parameters measured in OCT that would discriminate between benign and malignant lesions.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jun 2016

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2016

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

July 28, 2016

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 2, 2016

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2017

Completed
Last Updated

April 4, 2019

Status Verified

March 1, 2019

Enrollment Period

1.5 years

First QC Date

July 28, 2016

Last Update Submit

April 2, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • composite endpoint

    thickness of the epidermis (µm), thickness of the dermis (µm), limit of epidermis/dermis, homogeneity of the epidermis, homogeneity and structure of the papillary dermis, vascular network associated, homogeneity of the reticular dermis, wall of vacuoles and nodules (presence or absence)

    at baseline

Secondary Outcomes (4)

  • implementation duration

    at baseline

  • acquisition practices duration

    at baseline

  • the duration of analysis image

    at baseline

  • utility of labeling with a dye for histology to locate the lesion

    at baseline

Study Arms (1)

Optical Coherence Tomography (OCT)

EXPERIMENTAL
Device: Optical Coherence Tomography (OCT) with VivosightDevice: Optical Coherence Tomography (OCT) with Skintell

Interventions

OCT used is Vivosight for diagnosis

Also known as: VIVOSIGHT (Michelson Diagnostics Ltd, Maidstone, Kent, UK)
Optical Coherence Tomography (OCT)

OCT used is Skintell for diagnosis

Also known as: SKINTELL (Agfa HealthCare, Heverlee, Belgium)
Optical Coherence Tomography (OCT)

Eligibility Criteria

Age50 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with suspicious skin lesions of malignant tumor (mostly non-melanoma: basal cell carcinoma, epidermoid carcinoma and actinic keratoses, or melanoma: melanoma, nevi) requiring biopsy / surgical excision;
  • consent signed

You may not qualify if:

  • Any dermatosis, hyperalgesic lesion, and / or infected and / or topography making it impossible measurements;
  • pregnant and nursing women
  • patients under tutorship or curatorship

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Mixed Tumor, MalignantCarcinomaKeratosis

Interventions

Tomography, Optical Coherence

Condition Hierarchy (Ancestors)

Neoplasms, Complex and MixedNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Tomography, OpticalOptical ImagingDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisTomographyInvestigative Techniques

Study Officials

  • Jean Luc PERROT, MD

    Centre Hospitalier Universitaire de Saint Etienne

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 28, 2016

First Posted

August 2, 2016

Study Start

June 1, 2016

Primary Completion

December 1, 2017

Study Completion

December 1, 2017

Last Updated

April 4, 2019

Record last verified: 2019-03

Data Sharing

IPD Sharing
Will not share